These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 17159117)

  • 1. Myeloperoxidase predicts risk of vasculopathic events in hemizgygous males with Fabry disease.
    Kaneski CR; Moore DF; Ries M; Zirzow GC; Schiffmann R
    Neurology; 2006 Dec; 67(11):2045-7. PubMed ID: 17159117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry.
    Ortiz A; Cianciaruso B; Cizmarik M; Germain DP; Mignani R; Oliveira JP; Villalobos J; Vujkovac B; Waldek S; Wanner C; Warnock DG
    Nephrol Dial Transplant; 2010 Mar; 25(3):769-75. PubMed ID: 19846394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry.
    Sims K; Politei J; Banikazemi M; Lee P
    Stroke; 2009 Mar; 40(3):788-94. PubMed ID: 19150871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry.
    Hopkin RJ; Cabrera G; Charrow J; Lemay R; Martins AM; Mauer M; Ortiz A; Patel MR; Sims K; Waldek S; Warnock DG; Wilcox WR
    Mol Genet Metab; 2016 Sep; 119(1-2):151-9. PubMed ID: 27510433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enzyme replacement therapy in Fabry disease patients undergoing dialysis: effects on quality of life and organ involvement.
    Pisani A; Spinelli L; Sabbatini M; Andreucci MV; Procaccini D; Abbaterusso C; Pasquali S; Savoldi S; Comotti C; Cianciaruso B
    Am J Kidney Dis; 2005 Jul; 46(1):120-7. PubMed ID: 15983965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value of the CHA
    Liu D; Hu K; Schmidt M; Müntze J; Maniuc O; Gensler D; Oder D; Salinger T; Weidemann F; Ertl G; Frantz S; Wanner C; Nordbeck P
    Clin Res Cardiol; 2018 Dec; 107(12):1111-1121. PubMed ID: 29797054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular events in patients with fabry disease natural history data from the fabry registry.
    Patel MR; Cecchi F; Cizmarik M; Kantola I; Linhart A; Nicholls K; Strotmann J; Tallaj J; Tran TC; West ML; Beitner-Johnson D; Abiose A
    J Am Coll Cardiol; 2011 Mar; 57(9):1093-9. PubMed ID: 21349401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of sex and phenotype on cardiac outcomes in patients with Fabry disease.
    El Sayed M; Hirsch A; Boekholdt M; van Dussen L; Datema M; Hollak C; Langeveld M
    Heart; 2021 Dec; 107(23):1889-1897. PubMed ID: 33568430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma globotriaosylsphingosine (lysoGb3) could be a biomarker for Fabry disease with a Chinese hotspot late-onset mutation (IVS4+919G>A).
    Liao HC; Huang YH; Chen YJ; Kao SM; Lin HY; Huang CK; Liu HC; Hsu TR; Lin SP; Yang CF; Fann CS; Chiu PC; Hsieh KS; Fu YC; Ke YY; Lin CY; Tsai FJ; Wang CH; Chao MC; Yu WC; Chiang CC; Niu DM
    Clin Chim Acta; 2013 Nov; 426():114-20. PubMed ID: 24055776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anderson-Fabry disease and the heart.
    O'Mahony C; Elliott P
    Prog Cardiovasc Dis; 2010; 52(4):326-35. PubMed ID: 20109602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anderson-Fabry disease: a multiorgan disease.
    Tuttolomondo A; Pecoraro R; Simonetta I; Miceli S; Pinto A; Licata G
    Curr Pharm Des; 2013; 19(33):5974-96. PubMed ID: 23448451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ascending aortic remodelling in Fabry disease after long-term enzyme replacement therapy.
    Monney P; Qanadli SD; Hajdu S; Tran C; Schwitter J; Dormond O; Barbey F
    Swiss Med Wkly; 2017; 147():w14517. PubMed ID: 29120015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular outcomes in Fabry disease are linked to severity of chronic kidney disease.
    Talbot AS; Lewis NT; Nicholls KM
    Heart; 2015 Feb; 101(4):287-93. PubMed ID: 25381325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term changes in arterial structure and function and left ventricular geometry after enzyme replacement therapy in patients affected with Fabry disease.
    Collin C; Briet M; Tran TC; Beaussier H; Benistan K; Bensalah M; Mousseaux E; Froissart M; Bozec E; Laurent S; Boutouyrie P; Germain DP
    Eur J Prev Cardiol; 2012 Feb; 19(1):43-54. PubMed ID: 21450622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paraoxonase (PON1) gene polymorphisms in Fabry disease: correlation with renal disease.
    Shemesh T; Whybra C; Delgado-Sanchez S; Beck M; Elstein D; Altarescu G
    Nephron Clin Pract; 2010; 116(4):c289-93. PubMed ID: 20639675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular endothelial growth factor (VEGF-a) in Fabry disease: association with cutaneous and systemic manifestations with vascular involvement.
    Zampetti A; Gnarra M; Borsini W; Giurdanella F; Antuzzi D; Piras A; Smaldone C; Pieroni M; Cadeddu C; de Waure C; Feliciani C
    Cytokine; 2013 Mar; 61(3):933-9. PubMed ID: 23332617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease.
    Germain DP; Charrow J; Desnick RJ; Guffon N; Kempf J; Lachmann RH; Lemay R; Linthorst GE; Packman S; Scott CR; Waldek S; Warnock DG; Weinreb NJ; Wilcox WR
    J Med Genet; 2015 May; 52(5):353-8. PubMed ID: 25795794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of patients treated through the Canadian Fabry disease initiative.
    Sirrs SM; Bichet DG; Casey R; Clarke JT; Lemoine K; Doucette S; West ML;
    Mol Genet Metab; 2014 Apr; 111(4):499-506. PubMed ID: 24534763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fabry disease: focus on cardiac manifestations and molecular mechanisms.
    Perrot A; Osterziel KJ; Beck M; Dietz R; Kampmann C
    Herz; 2002 Nov; 27(7):699-702. PubMed ID: 12439642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and clinical consequences of white matter lesions in Fabry disease: a systematic review.
    Körver S; Vergouwe M; Hollak CEM; van Schaik IN; Langeveld M
    Mol Genet Metab; 2018 Nov; 125(3):205-216. PubMed ID: 30213639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.